Status In progress
Process STA pre-2018
ID number 1098

Provisional Schedule

Expected publication 04 July 2018

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors Pfizer
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups None
Comparator companies Accord Healthcare (docetaxel, gemcitabine, paclitaxel, carboplatin, cisplatin) (not participating confidentiality agreement not signed)
  Actavis (docetaxel, gemcitabine, paclitaxel, vinorelbine, pemetrexed) (not participating confidentiality agreement not signed)
  Boehringer Ingelheim (nintedanib) (not participating confidentiality agreement not signed)
  Celgene (paclitaxel) (not participating confidentiality agreement not signed)
  Dr Reddy’s Laboratories (docetaxel, pemetrexed) (not participating confidentiality agreement not signed)
  Eli Lilly and Company (gemcitabine, pemetrexed) (not participating confidentiality agreement not signed)
  Hospira UK (docetaxel, paclitaxel, gemcitabine, carboplatin, cisplatin) (not participating confidentiality agreement not signed)
  Medac GmbH (docetaxel, paclitaxel, vinorelbine) (not participating confidentiality agreement not signed)
  Pierre Fabre (vinorelbine) (not participating confidentiality agreement not signed)
  Sandoz (cisplatin) (not participating confidentiality agreement not signed)
  Sanofi (docetaxel) (not participating confidentiality agreement not signed)
  Seacross Pharmaceuticals (docetaxel) (not participating confidentiality agreement not signed)
  Sun Pharmaceuticals UK Ltd (gemcitabine, carboplatin) (not participating confidentiality agreement not signed)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
31 May 2018 - 14 June 2018 Final appraisal determination: 1
28 March 2018 The committee met to discuss on crizotinib for treating ROS1-positive advanced non-small-cell lung cancer on 21 February 2018. The provisional/draft recommendation that the committee has made requires that the Institute conducts further work before the documentation can be issued. This is to ensure that the recommendation can be implemented once the guidance has been published.
21 February 2018 Committee meeting: 2
17 January 2018 - 07 February 2018 Appraisal consultation: 1
12 December 2017 Committee meeting: 1
30 May 2017 Invitation to participate
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance